Trial watch: DNA-based vaccines for oncological indications (Q56893452)

Europe PubMed Central

title

Trial watch: DNA-based vaccines for oncological indications (English)

0 references

Jonathan G Pol

4

0 references

Lorenzo Galluzzi

8

object named as

Lorenzo Galluzzi

0 references

Guido Kroemer

6

object named as

Guido Kroemer

0 references

Laurence Zitvogel

5

object named as

Laurence Zitvogel

0 references

author name string

Stefano Pierini

1

0 references

Renzo Perales-Linares

2

0 references

Mireia Uribe-Herranz

3

0 references

Andrea Facciabene

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

7

0 references

language of work or name

English

0 references

publication date

2017

0 references

published in

OncoImmunology

0 references

volume

6

0 references

issue

12

0 references

page(s)

e1398878

0 references

cites work

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Classification of current anticancer immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Control of Metastasis by NK Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Doubling the blockade for melanoma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Fine-tuning the CAR spacer improves T-cell potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

CAR-T cells are serial killers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Gardasil 9 joins the fight against cervix cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial watch: Naked and vectored DNA-based anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial watch: Dendritic cell-based anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: Peptide-based anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: DNA vaccines for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Preclinical and clinical development of DNA vaccines for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Privileged Antigen Presentation in Splenic B Cell Follicles Maximizes T Cell Responses in Prime-Boost Vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Maraba virus as a potent oncolytic vaccine vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Delivery of viral-vectored vaccines by B cells represents a novel strategy to accelerate CD8(+) T-cell recall responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Making It Personal: Neoantigen Vaccines in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

An immunogenic personal neoantigen vaccine for patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Human Tumor Antigens and Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Oncogenic cancer/testis antigens: prime candidates for immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The present status and future prospects of peptide-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DC vaccine generated by ALA-PDT-induced immunogenic apoptotic cells for skin squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

RNA-based drugs and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

RNA-Based Vaccines in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Technologies for enhanced efficacy of DNA vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Direct gene transfer into mouse muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with Stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA electrotransfer: its principles and an updated review of its therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccines: developing new strategies against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccine for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Karyotypic Aberrations in Oncogenesis and Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Personalized cancer vaccines: Targeting the cancer mutanome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tumor neoantigens: building a framework for personalized cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Improving DNA vaccine performance through vector design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Vector Design for Improved DNA Vaccine Efficacy, Safety and Production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccines: precision tools for activating effective immunity against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Safety and efficacy of DNA vaccines: plasmids vs. minicircles

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Clinical applications of DNA vaccines: current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial watch: DNA vaccines for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Improving vaccine efficacy against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Chemokine-enhanced DNA vaccination in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The future of immune checkpoint therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Chemo-immunotherapy mediates durable cure of orthotopic KrasG12D/p53-/- pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunogenic cell death in cancer and infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

In situ immunization via non-surgical ablation to prevent local and distant tumor recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Author's view: radiation and immunotherapy as systemic therapy for solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immune recognition of irradiated cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Role of Local Radiation Therapy in Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Radiotherapy: Changing the Game in Immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: Immunotherapy plus radiation therapy for oncological indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Treatment of HER2-positive breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Biomarkers of residual disease after neoadjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Chemokine Receptor Signaling and the Hallmarks of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

T-box transcription factor Brachyury in lung cancer cells inhibits macrophage infiltration by suppressing CCL2 and CCL4 chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

HER2-positive feline mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

21 January 2018

Feline Mammary Cancer.

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Molecular based subtyping of feline mammary carcinomas and clinicopathological characterization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The tyrosine phosphatase PTPN13/FAP-1 links calpain-2, TBI and tau tyrosine phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Expression of cancer-associated fibroblast-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch-Oncolytic viruses and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Suppression of antigen presentation by IL-10

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Dendritic cells continue to capture and present antigens after maturation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Four pathways of CD1 antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Antibodies designed as effective cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Using monoclonal antibodies to stimulate antitumor cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The CC chemokine CCL20 and its receptor CCR6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Molecular mechanism and function of CD40/CD40L engagement in the immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The role of CD40 expression in dendritic cells in cancer biology; a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

PMEL: a pigment cell-specific model for functional amyloid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Autodisplay: efficacious surface exposure of antigenic UreA fragments from Helicobacter pylori in Salmonella vaccine strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Advances in Immunotherapy for Melanoma: A Comprehensive Review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tools to define the melanoma-associated immunopeptidome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

NF-kappaB and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The two NF-kappaB activation pathways and their role in innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

NF‐κB and the link between inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Telomerase based anticancer immunotherapy and vaccines approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Telomerase as a Cancer Target. Development of New Molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Telomeres and telomerase in T cells of tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Novel anticancer therapeutics targeting telomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccines for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Designing effective vaccines for colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Recent progress in GM-CSF-based cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

In vivo Reprogramming of Cancer Metabolism by MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

MYC: Master Regulator of Immune Privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Human papillomaviruses and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Calreticulin and type I interferon: An unsuspected connection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunological off-target effects of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Imatinib: a targeted clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

MUC1 upregulation promotes immune resistance in tumor cells undergoing brachyury-mediated epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Targeting the androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Prostate cancer vaccines: Update on clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Discovery of mesothelin and exploiting it as a target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Interleukin-2 inhibits FMS-like tyrosine kinase 3 receptor ligand (flt3L)-dependent development and function of conventional and plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

PD-L1 blockade for urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Anti-PD-L1 inhibitor durvalumab in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Idiotypes as immunogens: facing the challenge of inducing strong therapeutic immune responses against the variable region of immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Results of a phase I-II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Molecular mechanisms of cisplatin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Inducible expression of cancer-testis antigens in human prostate cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Genome-Wide Epigenetic Modifications in Cancer

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Edward Jenner and the history of smallpox and vaccination

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

Priming of Cytotoxic T Lymphocytes by DNA Vaccines: Requirement for Professional Antigen Presenting Cells and Evidence for Antigen Transfer from Myocytes

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5706602

DNA and Adenoviral Vectors Encoding Carcinoembryonic Antigen Fused to Immunoenhancing Sequences Augment Antigen-Specific Immune Response and Confer Tumor Protection

2 November 2018

1 reference

https://api.crossref.org/works/10.1080%2F2162402X.2017.1398878

Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

Assuring the quality, safety, and efficacy of DNA vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

Therapeutic HPV DNA vaccines

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

Altered peptide ligands make their entry

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

First-Ever CAR T-cell Therapy Approved in U.S.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29209575

12 December 2020